Long Non-Coding RNAs, Cell Cycle, and Human Breast Cancer

Yin, Qinan; Ma, Haodi; Bamunuarachchi, Gayan; Zheng, Xuewei; Ma, Yong

doi:10.1089/hum.2023.074

Cited by 10 publications

(1 citation statement)

References 179 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer (BC) is the most common malignancy in women and one of the three most common cancers worldwide, along with lung and colon cancer [ 1 – 3 ]. In 2020, BC was the most commonly diagnosed cancer in females after lung cancer, with an estimated 2.3 million new cases (11.7%), and the death rate reached 6.9% [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

The integration of multidisciplinary approaches revealed PTGES3 as a novel drug target for breast cancer treatment

Yin,

Ma,

Dong

et al. 2024

J Transl Med

Self Cite

View full text Add to dashboard Cite

Background The main challenge in personalized treatment of breast cancer (BC) is how to integrate massive amounts of computing resources and data. This study aimed to identify a novel molecular target that might be effective for BC prognosis and for targeted therapy by using network-based multidisciplinary approaches. Methods Differentially expressed genes (DEGs) were first identified based on ESTIMATE analysis. A risk model in the TCGA-BRCA cohort was constructed using the risk score of six DEGs and validated in external and clinical in-house cohorts. Subsequently, independent prognostic factors in the internal and external cohorts were evaluated. Cell viability CCK-8 and wound healing assays were performed after PTGES3 siRNA was transiently transfected into the BC cell lines. Drug prediction and molecular docking between PTGES3 and drugs were further analyzed. Cell viability and PTGES3 expression in two BC cell lines after drug treatment were also investigated. Results A novel six-gene signature (including APOOL, BNIP3, F2RL2, HINT3, PTGES3 and RTN3) was used to establish a prognostic risk stratification model. The risk score was an independent prognostic factor that was more accurate than clinicopathological risk factors alone in predicting overall survival (OS) in BC patients. A high risk score favored tumor stage/grade but not OS. PTGES3 had the highest hazard ratio among the six genes in the signature, and its mRNA and protein levels significantly increased in BC cell lines. PTGES3 knockdown significantly inhibited BC cell proliferation and migration. Three drugs (gedunin, genistein and diethylstilbestrol) were confirmed to target PTGES3, and genistein and diethylstilbestrol demonstrated stronger binding affinities than did gedunin. Genistein and diethylstilbestrol significantly inhibited BC cell proliferation and reduced the protein and mRNA levels of PTGES3. Conclusions PTGES3 was found to be a novel drug target in a robust six-gene prognostic signature that may serve as a potential therapeutic strategy for BC.

show abstract

Section: Introductionmentioning

confidence: 99%